NTV Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.4M Buy
+61,443
New +$3.32M 0.31% 77

Other funds holding CRSP

NTV Asset Management's CRSP Position: Q3 2026 in Review

NTV Asset Management opened a new position in CRISPR Therapeutics (CRSP) in Q3 2026: 61,443 shares worth $3.4M. The stake represents 0.31% of the portfolio and ranks #77 among its holdings.

502 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.

  • NTV Asset Management held 61,443 shares of CRISPR Therapeutics worth $3.4M as of Q3 2026.
  • CRISPR Therapeutics was a new NTV Asset Management position in Q3 2026.
  • CRISPR Therapeutics made up 0.31% of NTV Asset Management's portfolio in Q3 2026, its #77 holding.
  • 502 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.

Based on NTV Asset Management's 13F filing for Q3 2026, filed 23 Oct 2026.